CORV - Correvio Pharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Correvio Pharma Corp.

1441 Creekside Drive
6th Floor
Vancouver, BC V6J 4S7

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark H. N. CorriganCEO & DirectorN/AN/A1958
Mr. Justin A. Renz CPA, MST, MBACFO & PresN/AN/A1972
Ms. Sheila M. GrantChief Operating OfficerN/AN/AN/A
Mr. David D. McMastersGen. CounselN/AN/A1959
Dr. William L. HunterExec. Officer & DirectorN/AN/A1963
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. Its portfolio of marketed brands also comprise Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome; and Esmocard and Esmocard Lyo (esmolol hydrochloride), a short-acting betablocker used to control rapid heart rate in various cardiovascular indications. The company's product candidates that are in development include Trevyent, a drug device combination that is designed to deliver treprostinil for pulmonary arterial hypertension. Correvio Pharma Corp. is headquartered in Vancouver, Canada.

Corporate Governance

Correvio Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.